See how excellent preparations may be key to colorectal cancer (CRC) detection
Colorectal cancer detection should be maximized with effective bowel preparations that achieve clear, visible results. These images of the colon illustrate the difference in cleansing that an excellent bowel prep makes. They clearly demonstrate how adopting an excellent bowel prep can maximize clinical standards in practice.
Colorectal cancer screening statistics
Inadequate bowel preparations may undermine colonoscopy for
CRC detection
Clinical trials demonstrated that poor bowel preparations significantly lower detection rates, particularly in the ascending colon2
Clarity in the ascending colon is vital for flat lesion detection
- Two large studies have demonstrated that adequate bowel preparation significantly improves detection rates of all adenomas (small, large, and flat)2
- Flat lesions are 10 times more likely to be cancerous than polyps, regardless of size3
- Approximately 37% of flat lesions are found in the ascending colon3
In a prospective clinical trial evaluating split dosing or same-day dosing vs evening-only dosing, the total number of flat lesions detected in patients who received some preparation the same day as the colonoscopy was significantly higher than in patients prepared the day before (P=0.02).4
There is a critical need to maximize CRC detection with colonoscopy
- The majority of CRCs can be prevented through early detection with colonoscopy5
- 50% of interval cancers are likely to result from missed lesions during colonoscopy6
Important Safety Information about MOVIPREP
MOVIPREP® (PEG-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid for oral solution) is an osmotic laxative indicated for cleansing of the colon as a preparation for colonoscopy in adults 18 years of age or older. MOVIPREP is contraindicated in patients with gastrointestinal (GI) obstruction, bowel perforation, gastric retention, ileus, toxic colitis or toxic megacolon, and patients who have had a severe hypersensitivity reaction to any of its components. MOVIPREP should be used with caution in patients at risk of or with fluid and electrolyte abnormalities, hyponatremia, arrhythmias, seizures, in patients with impaired renal function or patients taking concomitant medications that affect renal function, patients with known or suspected inflammatory bowel disease, patients with suspected GI obstruction or perforation, patients at risk for aspiration, and patients with glucose-6-phosphate dehydrogenase deficiency. Most common adverse reactions for split dosing (incidence ≥5%) are malaise, nausea, abdominal pain, vomiting, and upper abdominal pain. The most common adverse reactions for evening only dosing (incidence ≥5%) are abdominal distension, anal discomfort, thirst, nausea, abdominal pain, sleep disorder, rigors, hunger, malaise, vomiting, and dizziness. MOVIPREP contains 233 mg of phenylalanine per treatment. Advise patients to hydrate adequately before, during, and after the use of MOVIPREP.
You are encouraged to report negative side effects to the FDA. Visit www.fda.gov/safety/medwatch/ or call 1-800-FDA-1088.
Complete Prescribing Information 
For Dummies is a registered trademark of Wiley Publishing, Inc.
References: 1. Data on file, Salix Pharmaceuticals, Inc. 2. Froehlich F, Wietlisbach V, Gonvers JJ, Burnand B. Impact of colonic cleansing on quality and diagnostic yield of colonoscopy: The European panel of appropriateness of gastrointestinal endoscopy European multicenter study. Gastrointest Endosc. 2005;61:378-384. 3. Soetikno RM, Kaltenbach T, Rouse RV, et al. Prevalence of non polypoid (flat and depressed) colorectal neoplasms in asymptomatic and symptomatic adults. JAMA. 2008;299:1027-1035. 4. Parra-Blanco A, Nicolas-Perez D, Gimeno-Garcia A, et al. The timing of bowel preparation before colonoscopy determines the quality of cleansing, and is a significant factor contributing to the detection of flat lesions: a randomized study. World J Gastroenterol. 2006;12:6161-6166. 5. Colon cancer screening. American Society for Gastrointestinal Endoscopy Web site. http://www.asge.org/pressroomindex.aspx?id=552. Accessed April 22, 2011. 6. Bechtler M, Eickhoff A, Riemann JF. Interval colon cancer and possible causes. Dstch Med Wochenschr. 2008;133:2458-2462.